New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
14:11 EDTTKMRTekmira lipid nanoparticle targeting Marburg virus highlighted in journal
Tekmira Pharmaceuticals announced the publication of data in a peer-reviewed scientific journal which highlights positive results in an animal model of Marburg virus infection enabled by Tekmira's lipid nanoparticle technology. Tekmira, along with its collaborators at the University of Texas Medical Branch at Galveston, USA, published data demonstrating complete protection of nonhuman primates against lethal Marburg virus-Angola hemorrhagic fever when treatment began even up to three days following infection. The study appears in the August 20 edition of the journal Science Translational Medicine. The study was designed to determine whether it is possible to protect animals against a lethal MARV-Angola infection when treatment was started at a point when animals have detectable levels of the virus in their system and already show the first clinical signs of disease.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
19:33 EDTTKMRTekmira shareholders vote for OnCore Biopharma
Subscribe for More Information
March 2, 2015
06:28 EDTTKMRFujifilm CEO says 'ready' for large orders of Avigan drug for Ebola, WSJ reports
Fujifilm’s (FUJIY) Avigan drug, which has shown signs of efficacy against the Ebola virus, has drawn interest from about 20 countries, The Wall Street Journal reports, citing comments made by CEO Shigetaka Komori. The drug was developed by Toyama Chemical, a Fujifilm unit, and Komori said the company is ready for large orders. Other drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
February 27, 2015
13:24 EDTTKMRLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
February 26, 2015
11:32 EDTTKMRTekmira to host special shareholder meeting
Subscribe for More Information
05:27 EDTTKMRTekmira announces update to proxy circular on merger with OnCore
Tekmira Pharmaceuticals announced an update to persons who will serve as members of the board of the company upon completion of the company's proposed business combination with OnCore Biopharma, as described in the company's proxy circular regarding the transaction, dated February 4. The board of the combined company upon completion of the merger will consist of Vivek Ramaswamy, who will serve as chairman of the board, Mark Murray, Ph.D., Richard Henriques, Jr., Keith Manchester, Frank Karbe, William T. Symonds, Pharm. D., and Herbert Conrad. Daniel Kisner, M.D., will not serve as a director or vice chairman of the board for the combined company.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use